For example, Halden et al. demonstrated infusion of the incretin hormone glucagon-like peptide 1 (GLP-1) during fasting and hyperglycaemic conditions in patients with PTDM compared with normal glucose tolerance, rectified pathophysiological defects like hyperglucagonemia, and diminished first- and second-phase insulin secretion [25]. The gene discussed is GCG; the disease is glucose measurement.